Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Jan 2019 Results published in the Internet Document
- 13 Nov 2018 Results of post-hoc analysis presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Apr 2018 Results of a population pharmacokinetics and exposure-response analysis from NCT02097277, NCT02413372 and one more study, presented at The International Liver Congress 2018.